Irritable bowel syndrome: Emerging paradigm in pathophysiology

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2456-2469

  Lee, Yoo Jin ^a   Park, Kyung Sik ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Diet; Enteroendocrine cell; Genetics; Immunologic; Inflammation; Irritable bowel syndrome; Microbiota; Pathophysiology

Indexed keywords

CALGRANULIN; CHROMOGRANIN; CORTICOTROPIN RELEASING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; NEUROPEPTIDE S; NEUROTRANSMITTER; SEROTONIN; TOLL LIKE RECEPTOR; AUTACOID;

ABSORPTION; ARTICLE; BILE ACID SYNTHESIS; CELIAC DISEASE; COLON BIOPSY; FOOD ALLERGY; GASTROINTESTINAL MOTILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPERSENSITIVITY; IMMUNOHISTOLOGY; INFLAMMATION; INTESTINE FLORA; IRRITABLE COLON; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; ANIMAL; DIET; ENTEROENDOCRINE CELL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INNERVATION; INTESTINE; METABOLISM; MICROBIOLOGY; PHENOTYPE; PROGNOSIS; RISK FACTOR;

ANIMALS; DIET; ENTEROENDOCRINE CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INTESTINES; IRRITABLE BOWEL SYNDROME; PHENOTYPE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896811215     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2456     Document Type: Article

References (197)

1. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G775-G785 [PMID: 22837345 DOI: 10.1152/ ajpgi.00155.2012]
2. Ballou SK, Keefer L. Multicultural considerations in the diagnosis and management of irritable bowel syndrome: a selective summary. Eur J Gastroenterol Hepatol 2013; 25: 1127-1133 [PMID: 23778308 DOI: 10.1097/MEG.0b013e3283632bf2]
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/ j.gastro.2005.11.061]
4. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209 [PMID: 17005763 DOI: 10.1136/gut.2006.100594]
5. Mearin F, Pérez-Oliveras M, Perelló A, Vinyet J, Ibañez A, Coderch J, Perona M. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104 [PMID: 16012939]
6. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-2516 [PMID: 16279907 DOI: 10.1111/j.1572-0241.2005.00257.x]
7. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/ gutjnl-2012-302167]
8. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol 2012; 5: 261-268 [PMID: 22778791 DOI: 10.1177/1756283x11436241]
9. Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 2012; 107: 440-447 [PMID: 22233694 DOI: 10.1038/ajg.2011.458]
10. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-564 [PMID: 12241674 DOI: 10.1016/s0140-6736(02)09712-x]
11. Martínez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, Santos J, Vicario M. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62: 1160-1168 [PMID: 22637702 DOI: 10.1136/gutjnl-2012-302093]
12. Narducci F, Bassotti G, Gaburri M, Morelli A. Twenty four hour manometric recording of colonic motor activity in healthy man. Gut 1987; 28: 17-25 [PMID: 3817580]
13. Bassotti G, Gaburri M. Manometric investigation of highamplitude propagated contractile activity of the human colon. Am J Physiol 1988; 255: G660-G664 [PMID: 3189553]
14. RITCHIE JA, ARDRAN GM, TRUELOVE SC. Motor activity of the sigmoid colon of humans. A combined study by intraluminal pressure recording and cineradiography. Gastroenterology 1962; 43: 642-668 [PMID: 13974070]
15. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499-1506 [PMID: 11374689 DOI: 10.1111/ j.1572-0241.2001.03804.x]
16. Choi MG, Camilleri M, O'Brien MD, Kammer PP, Hanson RB. A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. Am J Gastroenterol 1997; 92: 297-302 [PMID: 9040210]
17. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25: 404-413 [PMID: 7379673]
18. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131 [PMID: 12454866 DOI: 10.1053/ gast.2002.37095]
19. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76-83 [PMID: 7785677]
20. Prott G, Shim L, Hansen R, Kellow J, Malcolm A. Relationships between pelvic floor symptoms and function in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 764-769 [PMID: 20456760 DOI: 10.1111/j.1365-2982.2010.01503.x]
21. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 2: 1-9 [PMID: 15335408 DOI: 10.1111/j.1365-2036.2004.02036.x]
22. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777 [PMID: 12055583]
23. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-1123 [PMID: 17919487 DOI: 10.1053/ j.gastro.2007.07.024]
24. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Evaluation of colonic sensory thresholds in IBS patients using a barostat. Definition of optimal conditions and comparison with healthy subjects. Dig Dis Sci 1994; 39: 449-457 [PMID: 8131679]
25. Costantini M, Sturniolo GC, Zaninotto G, D'Incà R, Polo R, Naccarato R, Ancona E. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci 1993; 38: 206-212 [PMID: 8093869]
26. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-827 [PMID: 7720476]
27. Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995; 108: 636-643 [PMID: 7875466]
28. Walker LS, Garber J, Smith CA, Van Slyke DA, Claar RL. The relation of daily stressors to somatic and emotional symptoms in children with and without recurrent abdominal pain. J Consult Clin Psychol 2001; 69: 85-91 [PMID: 11302281]
29. Awad RA, Camacho S, Martín J, Ríos N. Rectal sensation, pelvic floor function and symptom severity in Hispanic population with irritable bowel syndrome with constipation. Colorectal Dis 2006; 8: 488-493 [PMID: 16784468 DOI: 10.1111/ j.1463-1318.2006.01038.x]
30. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-27 [PMID: 11115818]
31. Simrén M, Agerforz P, Björnsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2007; 19: 20-29 [PMID: 17187585 DOI: 10.1111/j.1365-2982.2006.00849. x]
32. Dickhaus B, Mayer EA, Firooz N, Stains J, Conde F, Olivas TI, Fass R, Chang L, Mayer M, Naliboff BD. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 135-143 [PMID: 12526949 DOI: 10.1111/j.1572-0241.2003.07156.x]
33. Posserud I, Agerforz P, Ekman R, Björnsson ES, Abrahamsson H, Simrén M. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102-1108 [PMID: 15247175 DOI: 10.1136/gut.2003.017962]
34. Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-793 [PMID: 19665956 DOI: 10.1016/j.dld.2009.07.006]
35. Wilhelmsen I. Brain-gut axis as an example of the biopsycho-social model. Gut 2000; 47 Suppl 4: iv5-i7; discussion iv10 [PMID: 11076893]
36. Murray CD, Flynn J, Ratcliffe L, Jacyna MR, Kamm MA, Emmanuel AV. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome. Gastroenterology 2004; 127: 1695-1703 [PMID: 15578507]
37. Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 2007; 42 Suppl 17: 48-51 [PMID: 17238026 DOI: 10.1007/ s00535-006-1942-7]
38. Fukudo S, Saito K, Sagami Y, Kanazawa M. Can modulating corticotropin releasing hormone receptors alter visceral sensitivity? Gut 2006; 55: 146-148 [PMID: 16407379 DOI: 10.1136/gut.2005.070888]
39. Fukudo S, Nomura T, Hongo M. Impact of corticotropinreleasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845-849 [PMID: 9691924]
40. Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, Shoji T, Karahashi K, Hongo M, Fukudo S. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004; 53: 958-964 [PMID: 15194643]
41. Hamaguchi T, Kano M, Rikimaru H, Kanazawa M, Itoh M, Yanai K, Fukudo S. Brain activity during distention of the descending colon in humans. Neurogastroenterol Motil 2004; 16: 299-309 [PMID: 15198652 DOI: 10.1111/j.1365-2982.2004.00498. x]
42. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409 [PMID: 15911167 DOI: 10.1016/j.pain.2005.03.023]
43. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118: 842-848 [PMID: 10784583]
44. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 12055584]
45. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the ir-ritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457 [PMID: 11012945]
46. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400 [PMID: 19174797 DOI: 10.1038/ajg.2008.94]
47. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hébuterne X. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473 [PMID: 18194987 DOI: 10.1136/gut.2007.127068]
48. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-929 [PMID: 18252749 DOI: 10.1136/gut.2007.138982]
49. Ohman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-986 [PMID: 16234043]
50. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979 [PMID: 12454854 DOI: 10.1053/gast.2002.37059]
51. Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjövall H, Simrén M. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-1212 [PMID: 19367268 DOI: 10.1038/ajg.2009.116]
52. Martínez C, González-Castro A, Vicario M, Santos J. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 2012; 6: 305-315 [PMID: 22844557 DOI: 10.5009/gnl.2012.6.3.305]
53. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920 [PMID: 17383420 DOI: 10.1053/j.gastro.2007.01.046]
54. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O' Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311 [PMID: 16472586 DOI: 10.1053/j.gastro.2005.11.033]
55. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 1789-1794; quiz 1795 [PMID: 20389294 DOI: 10.1038/ajg.2010.156]
56. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-192 [PMID: 6826101]
57. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-474 [PMID: 15139501]
58. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hébuterne X, Piche T. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2013; Epub ahead of print [PMID: 23878165 DOI: 10.1136/ gutjnl-2012-304066]
59. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49: 743-745 [PMID: 11709500]
60. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-410 [PMID: 19174795 DOI: 10.1038/ajg.2008.86]
61. Aldhous MC, Noble CL, Satsangi J. Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One 2009; 4: e6285 [PMID: 19617917 DOI: 10.1371/journal. pone.0006285]
62. Park KS, Ahn SH, Hwang JS, Cho KB, Chung WJ, Jang BK, Kang YN, Kwon JH, Kim YH. A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci 2008; 53: 704-711 [PMID: 17717743 DOI: 10.1007/s10620-007-9930-1]
63. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn WJ, Loftus EV. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis 2013; 19: 550-553 [PMID: 23380937 DOI: 10.1097/MIB.0b013e31827febfd]
64. Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S, Autenrieth IB, Zipfel S, Frick JS. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 2011; 23: e479-e488 [PMID: 21883703 DOI: 10.1111/j.1365-2982.2011.01779.x]
65. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544 [PMID: 17661757 DOI: 10.1111/ j.1365-2036.2007.03399.x]
66. Stewart GT. Post-dysenteric colitis. Br Med J 1950; 1: 405-409 [PMID: 15410136]
67. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-1583 [PMID: 12873581 DOI: 10.1111/j.1572-0241.2003.07542.x]
68. Camilleri M, Carlson P, McKinzie S, Zucchelli M, D'Amato M, Busciglio I, Burton D, Zinsmeister AR. Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. Neurogastroenterol Motil 2011; 23: 935-e398 [PMID: 21752155 DOI: 10.1111/j.1365-2982.2011.01749.x]
69. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut 2013; 62: 985-994 [PMID: 22684480 DOI: 10.1136/gutjnl-2011-301213]
70. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009; 19: 141-150, vii [PMID: 19232285 DOI: 10.1016/ j.giec.2008.12.004]
71. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Lowgrade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Mol Med Rep 2013; 7: 1081-1085 [PMID: 23417076 DOI: 10.3892/mmr.2013.1320]
72. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406 [PMID: 10026328]
73. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101 [PMID: 15247174 DOI: 10.1136/ gut.2003.021154]
74. McKeown ES, Parry SD, Stansfield R, Barton JR, Welfare MR. Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil 2006; 18: 839-843 [PMID: 16918763 DOI: 10.1111/ j.1365-2982.2006.00821.x]
75. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga AM, Lanzini A. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107: 891-899 [PMID: 22525306 DOI: 10.1038/ ajg.2012.102]
76. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-5163 [PMID: 23066308 DOI: 10.3748/wjg.v18.i37.5151]
77. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659 [PMID: 14724817]
78. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007; 45 Suppl 2: S115-S119 [PMID: 18185071 DOI: 10.1097/MPG.0b013e31812e66da]
79. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 2010; 161: 19-27 [PMID: 20408856 DOI: 10.1111/j.1365-2249.2010.04150. x]
80. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526 [PMID: 12631663]
81. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-1118 [PMID: 18694443 DOI: 10.1111/j.1365-2982.2008.01166.x]
82. Cremon C, Pallotti F, Bacchilega M, Stanghellini V, Corinaldesi R, Barbara G. Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Rev Gastroenterol Hepatol 2008; 2: 735-740 [PMID: 19090734 DOI: 10.1586/17474124.2.6.735]
83. Gewirtz AT. Flag in the crossroads: flagellin modulates innate and adaptive immunity. Curr Opin Gastroenterol 2006; 22: 8-12 [PMID: 16319670]
84. Bengtson MB, Rønning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754-1759 [PMID: 17008364 DOI: 10.1136/gut.2006.097287]
85. Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am 2011; 40: 45-67 [PMID: 21333900 DOI: 10.1016/j.gtc.2010.12.011]
86. Romero-Valdovinos M, Gudiño-Ramírez A, Reyes-Gordillo J, Martínez-Flores WA, Ramírez-Miranda ME, Maravilla P, Olivo-Díaz A. Interleukin-8 and-10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep 2012; 39: 8837-8843 [PMID: 22740130 DOI: 10.1007/s11033-012-1745-2]
87. Gonsky R, Deem RL, Targan SR. Multiple activating and repressive cis-promoter regions regulate TNFSF15 expression in human primary mononuclear cells. Cytokine 2013; 63: 36-42 [PMID: 23642711 DOI: 10.1016/j.cyto.2013.04.004]
88. Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull 2008; 87: 17-30 [PMID: 18753178 DOI: 10.1093/bmb/ ldn031]
89. Zucchelli M, Camilleri M, Andreasson AN, Bresso F, Dlugosz A, Halfvarson J, Törkvist L, Schmidt PT, Karling P, Ohlsson B, Duerr RH, Simren M, Lindberg G, Agreus L, Carlson P, Zinsmeister AR, D'Amato M. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011; 60: 1671-1677 [PMID: 21636646 DOI: 10.1136/gut.2011.241877]
90. Swan CDN, Campbell E, Hastings M, Neal KR, Dukes GE, Whorwell PJ, Hall I, Spiller RC. Association of proinflammatory genetic polymorphisms with the irritable bowel syndrome (IBS): phenotype and genotype correlation (Abstract). Gastroenterology 2011; 140: S525
91. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, Ducrotté P. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7: e42777 [PMID: 23028414 DOI: 10.1371/journal. pone.0042777]
92. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7017 [PMID: 11083826]
93. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-1513 [PMID: 20044998 DOI: 10.1053/j.gastro.2009.12.049]
94. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336 [PMID: 21102570 DOI: 10.1038/ajg.2010.438]
95. Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, Storr MA. Cytokines and irritable bowel syndrome: where do we stand? Cytokine 2012; 57: 201-209 [PMID: 22178716 DOI: 10.1016/j.cyto.2011.11.019]
96. Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 2005; 129: 131-141 [PMID: 16012943]
97. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed) 2009; 14: 2765-2778 [PMID: 19273235]
98. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994; 35: 669-674 [PMID: 8200563]
99. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-93 [PMID: 12477767]
100. Shiotani A, Kusunoki H, Kimura Y, Ishii M, Imamura H, Tarumi K, Manabe N, Kamada T, Hata J, Haruma K. S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 2013; 58: 2314-2323 [PMID: 23595519 DOI: 10.1007/s10620-013-2677-y]
101. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 979-986 [PMID: 17877505 DOI: 10.1111/ j.1365-2036.2007.03453.x]
102. Kumar S, Ranjan P, Mittal B, Ghoshal UC. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis 2012; 21: 31-38 [PMID: 22457857]
103. Wang YM, Chang Y, Chang YY, Cheng J, Li J, Wang T, Zhang QY, Liang DC, Sun B, Wang BM. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil 2012; 24: 560-565, e254-255 [PMID: 22435794 DOI: 10.1111/ j.1365-2982.2012.01902.x]
104. Saito YA, Locke GR, Zimmerman JM, Holtmann G, Slusser JP, de Andrade M, Petersen GM, Talley NJ. A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 465-470 [PMID: 17564628 DOI: 10.1111/ j.1365-2982.2007.00905.x]
105. Andresen V, Camilleri M, Kim HJ, Stephens DA, Carlson PJ, Talley NJ, Saito YA, Urrutia R, Zinsmeister AR. Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130: 1985-1994 [PMID: 16762621 DOI: 10.1053/ j.gastro.2006.03.017]
106. Saito YA, Larson JJ, Atkinson EJ, Ryu E, Almazar AE, Petersen GM, Talley NJ. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci 2012; 57: 2650-2657 [PMID: 22855291 DOI: 10.1007/s10620-012-2319-9]
107. Camilleri M, Carlson P, Zinsmeister AR, McKinzie S, Busciglio I, Burton D, Zucchelli M, D'Amato M. Neuropeptide S Receptor Induces Neuropeptide Expression and Associates With Intermediate Phenotypes of Functional Gastrointestinal Disorders. Gastroenterology 2010; 138: 98-107 [DOI: 10.1053/ j.gastro.2009.08.051]
108. Camilleri M, Carlson P, McKinzie S, Grudell A, Busciglio I, Burton D, Baxter K, Ryks M, Zinsmeister AR. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 2008; 294: G13-G19 [PMID: 17962356 DOI: 10.1152/ajpgi. 00371.2007]
109. Camilleri M. Genetics of human gastrointestinal sensation. Neurogastroenterol Motil 2013; 25: 458-466 [PMID: 23594334 DOI: 10.1111/nmo.12132]
110. Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptormediated in rats. Eur J Pharmacol 2000; 409: 207-211 [PMID: 11104836]
111. MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2004; 286: G863-G871 [PMID: 14701723 DOI: 10.1152/ajpgi.00482.2003]
112. Li YY, Cao MH, Goetz B, Chen CQ, Feng YJ, Chen CJ, Kasparek MS, Sibaev A, Storr M, Kreis ME. The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus. PLoS One 2013; 8: e67427 [PMID: 23844009 DOI: 10.1371/journal.pone.0067427]
113. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006; 291: G364-G371 [PMID: 16574988 DOI: 10.1152/ajpgi.00407.2005]
114. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-717 [PMID: 19570102 DOI: 10.1111/j.1365-2036.2009.04081.x]
115. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966 [PMID: 19346330 DOI: 10.1194/jlr. R900010-JLR200]
116. Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, Rao AS, Zinsmeister AR, Gores GJ. A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-1942 [PMID: 21396369 DOI: 10.1053/ j.gastro.2011.02.063]
117. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, Bunnett NW, Corvera CU. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22: 814-825, e227-228 [PMID: 20236244 DOI: 10.1111/ j.1365-2982.2010.01487.x]
118. Camilleri M, Vazquez-Roque MI, Carlson P, Burton D, Wong BS, Zinsmeister AR. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil 2011; 23: 995-999, e458 [PMID: 21883702 DOI: 10.1111/j.1365-2982.2011.01772.x]
119. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008; 103: 1557-1567 [PMID: 18513268 DOI: 10.1111/j.1572-0241.2008.01869.x]
120. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194 [PMID: 7121297]
121. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802-1805 [PMID: 15188510]
122. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382 [PMID: 15667495 DOI: 10.1111/ j.1572-0241.2005.40312.x]
123. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33 [PMID: 17631127 DOI: 10.1053/ j.gastro.2007.04.005]
124. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. Highthroughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615 [PMID: 18941009 DOI: 10.1136/gut.2007.133603]
125. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95 [PMID: 20015409 DOI: 10.1186/1471-230x-9-95]
126. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminaland mucosal-associated intestinal microbiota in diarrheapredominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301: G799-G807 [PMID: 21737778 DOI: 10.1152/ajpgi.00154.2011]
127. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-1189 [PMID: 9777836]
128. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005; 50: 758-766 [PMID: 15844715]
129. Bär F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, Böttner M, Wedel T. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21: 559-566, e16-17 [PMID: 19220758 DOI: 10.1111/j.1365-2982.2008.01258.x]
130. Lesniewska V, Rowland I, Laerke HN, Grant G, Naughton PJ. Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo. Exp Physiol 2006; 91: 229-237 [PMID: 16263800 DOI: 10.1113/expphysiol. 2005.031708]
131. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55: 191-196 [PMID: 16361309 DOI: 10.1136/gut.2005.070987]
132. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37 [PMID: 17159985 DOI: 10.1038/nm1521]
133. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 385-396 [PMID: 18532993 DOI: 10.1111/j.1365-2036.2008.03750.x]
134. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The util-ity of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-149; quiz 1050 [PMID: 19277023 DOI: 10.1038/ajg.2009.25]
135. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
136. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 1157-1160 [PMID: 16305730 DOI: 10.1111/j.1365-2036.2005.02690.x]
137. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 21: 1391-1395 [PMID: 15932370 DOI: 10.1111/j.1365-2036.2005.02493.x]
138. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010; 55: 2441-2449 [PMID: 20467896 DOI: 10.1007/s10620-010-1276-4]
139. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
140. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebocontrolled study. Am J Gastroenterol 2003; 98: 412-419 [PMID: 12591062 DOI: 10.1111/j.1572-0241.2003.07234.x]
141. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139-142 [PMID: 18217406]
142. Weinstock LB, Fern SE, Duntley SP. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 2008; 53: 1252-1256 [PMID: 17934858 DOI: 10.1007/s10620-007-0021-0]
143. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002; 47: 2639-2643 [PMID: 12498278]
144. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802-808 [PMID: 17148502 DOI: 10.1136/gut.2006.108712]
145. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187. e1-3 [PMID: 22885331 DOI: 10.1053/j.gastro.2012.08.002]
146. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566-1570 [PMID: 15984983 DOI: 10.1111/ j.1572-0241.2005.40795.x]
147. Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S, Hankins J, Norton N, Drossman D. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol 2007; 102: 1972-1982 [PMID: 17488254 DOI: 10.1111/ j.1572-0241.2007.01254.x]
148. Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013; 108: 634-641 [PMID: 23644955 DOI: 10.1038/ajg.2013.105]
149. Ostgaard H, Hausken T, Gundersen D, El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep 2012; 5: 1382-1390 [PMID: 22446969 DOI: 10.3892/mmr.2012.843]
150. Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Effects of dietary guidance on the symptoms, quality of life and habitual dietary intake of patients with irritable bowel syndrome. Mol Med Rep 2013; 8: 845-852 [PMID: 23820783 DOI: 10.3892/mmr.2013.1565]
151. Salvioli B, Serra J, Azpiroz F, Malagelada JR. Impaired small bowel gas propulsion in patients with bloating during intestinal lipid infusion. Am J Gastroenterol 2006; 101: 1853-1857 [PMID: 16817837 DOI: 10.1111/j.1572-0241.2006.00702.x]
152. Elsenbruch S, Holtmann G, Oezcan D, Lysson A, Janssen O, Goebel MU, Schedlowski M. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99: 703-710 [PMID: 15089905 DOI: 10.1111/ j.1572-0241.2004.04138.x]
153. Ng C, Malcolm A, Hansen R, Kellow J. Feeding and colonic distension provoke altered autonomic responses in irritable bowel syndrome. Scand J Gastroenterol 2007; 42: 441-446 [PMID: 17454853 DOI: 10.1080/00365520600965749]
154. Strobel S. Epidemiology of food sensitivity in childhood--with special reference to cow's milk allergy in infancy. Monogr Allergy 1993; 31: 119-130 [PMID: 8450842]
155. Kay AB, Lessof MH. Allergy. Conventional and alternative concepts. A report of the Royal College of Physicians Committee on Clinical Immunology and Allergy. Clin Exp Allergy 1992; 22 Suppl 3: 1-44 [PMID: 1422946]
156. Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990; 99: 1016-1020 [PMID: 2394324]
157. Parker TJ, Woolner JT, Prevost AT, Tuffnell Q, Shorthouse M, Hunter JO. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001; 13: 219-225 [PMID: 11293439]
158. Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol 2005; 40: 800-807 [PMID: 16109655 DOI: 10.1080/00 365520510015593]
159. Zuo XL, Li YQ, Li WJ, Guo YT, Lu XF, Li JM, Desmond PV. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007; 37: 823-830 [PMID: 17517095 DOI: 10.1111/j.1365-2222.2007.02727.x]
160. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464 [PMID: 15361495 DOI: 10.1136/gut.2003.037697]
161. Carroccio A, Brusca I, Mansueto P, Pirrone G, Barrale M, Di Prima L, Ambrosiano G, Iacono G, Lospalluti ML, La Chiusa SM, Di Fede G. A cytologic assay for diagnosis of food hypersensitivity in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010; 8: 254-260 [PMID: 19932763 DOI: 10.1016/j.cgh.2009.11.010]
162. Carroccio A, Brusca I, Mansueto P, Soresi M, D'Alcamo A, Ambrosiano G, Pepe I, Iacono G, Lospalluti ML, La Chiusa SM, Di Fede G. Fecal assays detect hypersensitivity to cow' s milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol 2011; 9: 965-971. e3 [PMID: 21839707 DOI: 10.1016/j.cgh.2011.07.030]
163. Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 141-162 [PMID: 21333905 DOI: 10.1016/j.gtc.2010.12.012]
164. Nanda R, James R, Smith H, Dudley CR, Jewell DP. Food intolerance and the irritable bowel syndrome. Gut 1989; 30: 1099-1104 [PMID: 2767507]
165. Zwetchkenbaum JF, Burakoff R. Food allergy and the irritable bowel syndrome. Am J Gastroenterol 1988; 83: 901-904 [PMID: 3046334]
166. Pearson DJ, Bentley SJ, Rix KJ, Roberts C. Food hypersensitivity and irritable bowel syndrome. Lancet 1983; 2: 746-747 [PMID: 6136876]
167. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998; 93: 2184-2190 [PMID: 9820394 DOI: 10.1111/ j.1572-0241.1998.00531.x]
168. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome--etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667-672 [PMID: 16391571 DOI: 10.1038/sj.ejcn.1602367]
169. El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG, Hausken T. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med 2012; 29: 723-731 [PMID: 22366773 DOI: 10.3892/ijmm.2012.926]
170. Barrett JS, Gearry RB, Muir JG, Irving PM, Rose R, Rosella O, Haines ML, Shepherd SJ, Gibson PR. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 2010; 31: 874-882 [PMID: 20102355 DOI: 10.1111/j.1365-2036.2010.04237.x]
171. de Roest RH, Dobbs BR, Chapman BA, Batman B, O'Brien LA, Leeper JA, Hebblethwaite CR, Gearry RB. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract 2013; 67: 895-903 [PMID: 23701141 DOI: 10.1111/ ijcp.12128]
172. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR, Muir JG. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-1373 [PMID: 20659225 DOI: 10.1111/j.1440-1746.2010.06370.x]
173. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996; 23: 280-286 [PMID: 8890079]
174. Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M, Pappas TN, Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1269-R1276 [PMID: 12676748 DOI: 10.1152/ajpregu.00442.2002]
175. Kamath PS, Hoepfner MT, Phillips SF. Short-chain fatty acids stimulate motility of the canine ileum. Am J Physiol 1987; 253: G427-G433 [PMID: 3661705]
176. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519, e114-115 [PMID: 19903265 DOI: 10.1111/j.1365-2982.2009.01427.x]
177. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313 [PMID: 19008265 DOI: 10.1136/bmj.a2313]
178. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154 [PMID: 19713235 DOI: 10.1136/ bmj.b3154]
179. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39-40 [PMID: 7912305]
180. Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 359-365. e1 [PMID: 23246645 DOI: 10.1016/j.cgh.2012.11.033]
181. El-Salhy M, Lomholt-Beck B, Gundersen D. The prevalence of celiac disease in patients with irritable bowel syndrome. Mol Med Rep 2011; 4: 403-405 [PMID: 21468583 DOI: 10.3892/ mmr.2011.466]
182. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001; 121: 1329-1338 [PMID: 11729112]
183. Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 844-50; quiz 769 [PMID: 17553753 DOI: 10.1016/j.cgh.2007.03.021]
184. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, Carlson P, Lamsam J, Janzow D, Eckert D, Burton D, Zinsmeister AR. A controlled trial of glutenfree diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-911. e3 [PMID: 23357715 DOI: 10.1053/ j.gastro.2013.01.049]
185. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with selfreported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-8. e1-320-8. e3 [PMID: 23648697 DOI: 10.1053/j.gastro.2013.04.051]
186. El-Salhy M, Vaali K, Dizdar V, Hausken T. Abnormal smallintestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 2010; 55: 3508-3513 [PMID: 20300845 DOI: 10.1007/s10620-010-1169-6]
187. Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008; 295: G260-G272 [PMID: 18556422 DOI: 10.1152/ajpgi.00056.2008]
188. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-332 [PMID: 11293643]
189. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-1076 [PMID: 16611266 DOI: 10.1111/j.1365-2036.2006.02858.x]
190. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-670 [PMID: 12692050]
191. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357 [PMID: 15822040]
192. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43 [PMID: 16401466 DOI: 10.1053/j.gastro.2005.09.031]
193. El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2010; 45: 1435-1439 [PMID: 20602602 DOI: 10.3109/00365521.2010.503965]
194. El-Salhy M, Mazzawi T, Gundersen D, Hausken T. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep 2012; 6: 1223-1225 [PMID: 22992886 DOI: 10.3892/mmr.2012.1087]
195. El-Salhy M, Wendelbo IH, Gundersen D. Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep 2013; 7: 1241-1244 [PMID: 23426642 DOI: 10.3892/mmr.2013.1325]
196. Sidhu R, Drew K, McAlindon ME, Lobo AJ, Sanders DS. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis? Inflamm Bowel Dis 2010; 16: 361 [PMID: 19575362 DOI: 10.1002/ibd.20982]
197. Sidhu R, McAlindon ME, Leeds JS, Skilling J, Sanders DS. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009; 18: 23-26 [PMID: 19337629]